

REMARKS

The application is to be amended as previously set forth. All amendments are made without prejudice or disclaimer.

A. Examiner Interview:

The applicants would like to thank the Examiner for the courtesy extended applicants' representatives at the interview of February 8, 2005. As discussed at the interview (and as is more thoroughly discussed herein), applicants would present the foregoing clarifying amendments to the application, which should place the application in condition for allowance. As also discussed at the interview, applicants supply herewith deposit receipt and Budapest Treaty declaration for the PER.C6 cell line. (See, e.g., claim 48).

B. The Claims:

As discussed with the Examiner, applicants have amended the claims to clarify that the cells, which form an element therein, are isolated adenovirus packaging cells comprising, in their genome, a first nucleic acid sequence encoding adenovirus ElA and ElB gene products but lacking nucleic acid sequences encoding adenovirus pIX.

If questions remain after consideration of the foregoing, the Office is kindly requested to contact applicants' attorney at the address or telephone number given herein.

Respectfully submitted,



Allen C. Turner

Registration No. 33,041

Attorney for Applicants

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Facsimile: 801-531-9168

Date: February 16, 2005